Table 5.
Expression levels of CK1δ in different types of cancer. Differential expression tendency of CK1δ is presented for different cancers. Subject ratio was calculated by comparing the number of patients significantly over- or under-expressing CK1δ to the number of patients analyzed in total. For each patient, log2 fold-change (log2FC) values greater than zero were considered to follow an over-expression trend, less than zero to follow an under-expression trend. Significance was justified based on adjusted P value (P value cutoff of 0.05). Data was obtained from BioXpress online tool (Wan et al., 2015, Dingerdissen et al., 2018).
| Cancer type | Subjects ratio | log2FC | P value | Adjusted P value | Significance | Expression trend |
|---|---|---|---|---|---|---|
| DOID:11054/urinary bladder cancer | 11/19 (57.89) | −0.25 | 0.046 | 0.095 | No | Down |
| DOID:3907/lung squamous cell carcinoma | 33/51 (64.71) | −0.06 | 0.351 | 0.402 | No | Down |
| DOID:10534/stomach cancer | 12/32 (37.5) | −0.1 | 0.224 | 0.406 | No | Down |
| DOID:263/kidney cancer | 36/72 (50.0) | −0.05 | 0.344 | 0.419 | No | Down |
| DOID:5041/esophageal cancer | 7/11 (63.64) | −0.11 | 0.435 | 0.59 | No | Down |
| DOID:11934/head and neck cancer | 17/43 (39.53) | −0.01 | 0.919 | 0.941 | No | Down |
| DOID:1781/thyroid cancer | 54/59 (91.53) | 0.16 | 0 | 0.002 | Yes | Up |
| DOID:1612/breast cancer | 53/114 (46.49) | 0.11 | 0.016 | 0.029 | Yes | Up |
| DOID:3571/liver cancer | 42/50 (84.0) | 0.21 | 0.008 | 0.049 | Yes | Up |
| DOID:10283/prostate cancer | 42/52 (80.77) | 0.09 | 0.04 | 0.071 | No | Up |
| DOID:4465/papillary renal cell carcinoma | 32/32 (100.0) | 0.26 | 0.051 | 0.176 | No | Up |
| DOID:3910/lung adenocarcinoma | 38/58 (65.52) | 0.08 | 0.207 | 0.717 | No | Up |
| DOID:4471/chromophobe adenocarcinoma | 18/25 (72.0) | 0.03 | 0.741 | 0.977 | No | Up |
| DOID:234/colon adenocarcinoma | 10/26 (38.46) | 0.04 | 0.663 | 1.000 | No | Up |